AU2018236267B2 - Methods for treating complement-mediated diseases and disorders - Google Patents

Methods for treating complement-mediated diseases and disorders Download PDF

Info

Publication number
AU2018236267B2
AU2018236267B2 AU2018236267A AU2018236267A AU2018236267B2 AU 2018236267 B2 AU2018236267 B2 AU 2018236267B2 AU 2018236267 A AU2018236267 A AU 2018236267A AU 2018236267 A AU2018236267 A AU 2018236267A AU 2018236267 B2 AU2018236267 B2 AU 2018236267B2
Authority
AU
Australia
Prior art keywords
seq
amino acid
acid sequence
antibody
region
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2018236267A
Other languages
English (en)
Other versions
AU2018236267A1 (en
Inventor
Sandip PANICKER
Graham Parry
Nancy E. Stagliano
Peter Van Vlasselaer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Recordati UK Ltd
Original Assignee
Recordati UK Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Recordati UK Ltd filed Critical Recordati UK Ltd
Publication of AU2018236267A1 publication Critical patent/AU2018236267A1/en
Assigned to Recordati UK Limited reassignment Recordati UK Limited Request for Assignment Assignors: BIOVERATIV USA INC.
Application granted granted Critical
Publication of AU2018236267B2 publication Critical patent/AU2018236267B2/en
Priority to AU2025204392A priority Critical patent/AU2025204392A1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Transplantation (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
AU2018236267A 2017-03-14 2018-03-14 Methods for treating complement-mediated diseases and disorders Active AU2018236267B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2025204392A AU2025204392A1 (en) 2017-03-14 2025-06-12 Methods for treating complement-mediated diseases and disorders

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201762471190P 2017-03-14 2017-03-14
US62/471,190 2017-03-14
US201762553059P 2017-08-31 2017-08-31
US62/553,059 2017-08-31
PCT/US2018/022462 WO2018170145A1 (en) 2017-03-14 2018-03-14 Methods for treating complement-mediated diseases and disorders

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2025204392A Division AU2025204392A1 (en) 2017-03-14 2025-06-12 Methods for treating complement-mediated diseases and disorders

Publications (2)

Publication Number Publication Date
AU2018236267A1 AU2018236267A1 (en) 2019-09-26
AU2018236267B2 true AU2018236267B2 (en) 2025-03-13

Family

ID=61873979

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2018236267A Active AU2018236267B2 (en) 2017-03-14 2018-03-14 Methods for treating complement-mediated diseases and disorders
AU2025204392A Pending AU2025204392A1 (en) 2017-03-14 2025-06-12 Methods for treating complement-mediated diseases and disorders

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2025204392A Pending AU2025204392A1 (en) 2017-03-14 2025-06-12 Methods for treating complement-mediated diseases and disorders

Country Status (14)

Country Link
US (1) US20210115116A1 (cg-RX-API-DMAC7.html)
EP (1) EP3596121A1 (cg-RX-API-DMAC7.html)
JP (3) JP7293122B2 (cg-RX-API-DMAC7.html)
KR (2) KR102934707B1 (cg-RX-API-DMAC7.html)
CN (1) CN110753701A (cg-RX-API-DMAC7.html)
AU (2) AU2018236267B2 (cg-RX-API-DMAC7.html)
BR (1) BR112019018950A2 (cg-RX-API-DMAC7.html)
CA (1) CA3055781A1 (cg-RX-API-DMAC7.html)
CR (1) CR20190468A (cg-RX-API-DMAC7.html)
IL (2) IL269174B2 (cg-RX-API-DMAC7.html)
MX (2) MX2019010994A (cg-RX-API-DMAC7.html)
SG (1) SG11201907583TA (cg-RX-API-DMAC7.html)
TW (2) TWI848905B (cg-RX-API-DMAC7.html)
WO (1) WO2018170145A1 (cg-RX-API-DMAC7.html)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014066744A2 (en) 2012-10-25 2014-05-01 True North Therapeutics, Inc. Anti-complement c1s antibodies and uses thereof
ES2912396T3 (es) 2012-11-02 2022-05-25 Bioverativ Usa Inc Anticuerpos anti-C1s del complemento y uso de los mismos
EP4212175A1 (en) 2015-04-06 2023-07-19 Bioverativ USA Inc. Humanized anti-c1s antibodies and methods of use thereof
IL326479A (en) 2016-10-12 2026-04-01 Bioverativ Usa Inc Anti-c1s antibodies and methods of use thereof
PL3893924T3 (pl) 2018-12-13 2025-01-13 argenx BV Przeciwciała przeciwko ludzkiemu czynnikowi c2b dopełniacza i sposoby zastosowania
GB2584105B (en) * 2019-05-21 2023-08-02 Argenx Bvba Methods of treating neuropathy
JP2023503611A (ja) * 2019-11-26 2023-01-31 オメロス コーポレーション 造血幹細胞移植に関連する特発性肺炎症候群（ｉｐｓ）および／または毛細血管漏出症候群（ｃｌｓ）および／または生着症候群（ｅｓ）および／または体液過剰（ｆｏ）を治療および／または予防するための方法
FI129383B (en) 2020-06-15 2022-01-31 Faron Pharmaceuticals Oy Stable anti-clever-1 antibody formulation
BR112023001942A2 (pt) * 2020-08-06 2023-02-28 Bioverativ Usa Inc Citocinas inflamatórias e fadiga em indivíduo com doença mediada por complemento
TW202304508A (zh) 2021-03-31 2023-02-01 美商百歐維拉提夫美國公司 減少冷凝集素疾病患者之手術相關溶血
US12252550B2 (en) 2021-05-20 2025-03-18 Dianthus Therapeutics Opco, Inc. Antibodies that bind to C1S and uses thereof
CN117642431B (zh) 2021-07-13 2025-07-15 迈威(美国)生物治疗有限公司 抗c1s抗体和其用途
CN114874329A (zh) * 2022-05-19 2022-08-09 江苏大学 一种补体活化C1s酶荧光检测试剂盒及检测方法与应用
MA71249A (fr) 2022-06-24 2025-04-30 Bioverativ Usa Inc. Méthodes de traitement de maladies médiées par complément
TW202426490A (zh) 2022-11-21 2024-07-01 美商黛安瑟斯醫療運營公司 結合ｃ１ｓ之抗體及其用途

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
JPH02500329A (ja) 1987-05-21 1990-02-08 クリエイテイブ・バイオマリキユールズ・インコーポレーテツド ターゲット化多機能蛋白質
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
DE69233482T2 (de) 1991-05-17 2006-01-12 Merck & Co., Inc. Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen
JP3540315B2 (ja) 1991-09-23 2004-07-07 メディカル リサーチ カウンシル キメラ抗体の製造−組合せアプローチ
DE69233528T2 (de) 1991-11-25 2006-03-16 Enzon, Inc. Verfahren zur Herstellung von multivalenten antigenbindenden Proteinen
DE614989T1 (de) 1993-02-17 1995-09-28 Morphosys Proteinoptimierung Verfahren für in vivo Selektion von Ligandenbindende Proteine.
ES2912396T3 (es) * 2012-11-02 2022-05-25 Bioverativ Usa Inc Anticuerpos anti-C1s del complemento y uso de los mismos
WO2015084999A1 (en) * 2013-12-06 2015-06-11 True North Therapeutics, Inc. Complement component biomarker assays

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
SANDIP PANICKER ET AL.: vol. 128, no. 22, 94, 2 December 2016 (2016-12-02), pages 1 - 10, XP002781262, Retrieved from the Internet <URL:http://www.bloodjournal.org/content/128/22/94> [retrieved on 20180523] *

Also Published As

Publication number Publication date
AU2025204392A1 (en) 2025-07-03
TW202513092A (zh) 2025-04-01
TWI848905B (zh) 2024-07-21
CN110753701A (zh) 2020-02-04
BR112019018950A2 (pt) 2020-04-22
JP2020511469A (ja) 2020-04-16
SG11201907583TA (en) 2019-09-27
TW201842931A (zh) 2018-12-16
US20210115116A1 (en) 2021-04-22
IL269174B1 (en) 2026-01-01
EP3596121A1 (en) 2020-01-22
IL269174A (en) 2019-11-28
WO2018170145A1 (en) 2018-09-20
MX2025010483A (es) 2025-10-01
JP2025072437A (ja) 2025-05-09
KR20260039796A (ko) 2026-03-20
KR102934707B1 (ko) 2026-03-06
JP7293122B2 (ja) 2023-06-19
KR20190128676A (ko) 2019-11-18
IL269174B2 (en) 2026-05-01
JP2023071824A (ja) 2023-05-23
CR20190468A (es) 2019-12-17
IL325084A (en) 2026-02-01
AU2018236267A1 (en) 2019-09-26
MX2019010994A (es) 2020-12-01
CA3055781A1 (en) 2018-09-20

Similar Documents

Publication Publication Date Title
KR102934707B1 (ko) 보체-매개된 질환 및 장애의 치료 방법
US20250188192A1 (en) Anti-complement c1s antibodies and uses thereof
US20230218753A1 (en) Humanized anti-c1s antibodies and methods of use thereof
US10717785B2 (en) Binding molecules that bind human complement factor C2 and uses thereof
ES2926700T3 (es) Anticuerpos anti Eotaxina-2 que reconocen quimiocinas de unión a CCR3 adicionales
JP2019516395A (ja) 第ｘｉ因子の活性部位に対するモノクローナル抗体及びその使用
WO2014066744A2 (en) Anti-complement c1s antibodies and uses thereof
US20250145696A1 (en) Methods for treating complement-mediated diseases and disorders
EP4444758A2 (en) Therapeutic antibodies that bind to the serine protease domain of masp-2 and uses thereof
HK40022920A (en) Methods for treating complement-mediated diseases and disorders
BR112018069283B1 (pt) Anticorpos monoclonais contra o sítio ativo de fator xi e usos dos mesmos

Legal Events

Date Code Title Description
PC1 Assignment before grant (sect. 113)

Owner name: RECORDATI UK LIMITED

Free format text: FORMER APPLICANT(S): BIOVERATIV USA INC.

FGA Letters patent sealed or granted (standard patent)